Clinical trial · Observational
Molecular and Genetic Analysis of Lung Cancer
NCT03029325CI-TRIAL-00083100recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Investigators use a genome-wide approach within a case-control design to identify SNPs that show evidence of association with lung cancer risk and survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Survival among patients at different stages of lung cancer and treatment will be measured using questionnaires along with medical chart data to monitor treatment and disease progression
- timeFrame
- 20 years
- description
- Study lung cancer development in a case control study. We will look at three separate outcome measures specified below
Secondary outcomes (3)
- measure
- Overall survival
- timeFrame
- 20 years
- description
- Measurement from time of diagnosis to death will be obtained
- measure
- Progression-free survival
- timeFrame
- 20 years
- description
- Time of diagnosis to disease progression (measured by metastasis)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * healthy controls: participants without evidence of any cancer * cases: pathology proven primary lung cancer Exclusion Criteria: * younger than 18 years old
References
Publications (0)
Data not yet available
No reference posted for this study.